Potential markers for the diagnosis of heart failure in patients with asthma
https://doi.org/10.36604/1998-5029-2024-92-143-152
Abstract
Asthma is a global health problem affecting countries worldwide. Currently, there is an increasing prevalence of patients with asthma who also suffer from concomitant cardiovascular pathology. The most common comorbidity is the coexistence of asthma and chronic heart failure (CHF). Given the overlap in clinical symptoms, differential diagnosis of these diseases at onset can be quite challenging. This raises the question of the possibility of early diagnosis of CHF in patients with asthma and the need to continue searching for etiopathogenic markers, as most laboratory indicators do not have 100% pathognomonic value. An analysis of available literature data on potential CHF markers in patients with a history of asthma was conducted. Information queries included the following set of keywords: "markers of chronic heart failure, bronchial asthma, N-terminal pro-brain natriuretic peptide (NTproBNP)." It was found that NTproBNP, currently considered the "gold standard" for diagnosing CHF, does not have absolute prognostic value, indicating the need for further search for highly sensitive and more specific markers. The article presents new biological markers, such as the fibrosis marker galectin-3, gamma-glutamyltransferase, growth stimulating factor, pentraxin 3, and tenascin C, which could be used for forecasting and risk stratification of heart failure development. It is concluded that the search for new biological markers would facilitate earlier diagnosis of CHF, thereby enabling timely therapy initiation, which could help reduce hospitalizations and improve the quality of life of patients.
About the Authors
M. B. Savich
Krasnoyarsk State Medical University;
Krasnoyarsk Regional Clinical Hospital
Russian Federation
Russian Federation
Mariya B. Savich, Cardiologist, Krasnoyarsk Regional Clinical Hospital, Postgraduate student, Department of Hospital Therapy and Immunology with Postgraduate Education Course, Krasnoyarsk State Medical University
1 Partizana Zheleznyaka Str., Krasnoyarsk, 660022,
3A Partizana Zheleznyaka Str., Krasnoyarsk, 660022
I. V. Demko
Krasnoyarsk State Medical University;
Krasnoyarsk Regional Clinical Hospital
Russian Federation
Russian Federation
Irina V. Demko, MD, PhD, DSc (Med.), Professor, Head of Department of Hospital Therapy and Immunology with Postgraduate Education Course, Krasnoyarsk State Medical University; Head of Pulmonary Allergology Сenter, Krasnoyarsk Regional Clinical Hospital
1 Partizana Zheleznyaka Str., Krasnoyarsk, 660022,
3A Partizana Zheleznyaka Str., Krasnoyarsk, 660022
E. A. Sobko
Krasnoyarsk State Medical University;
Krasnoyarsk Regional Clinical Hospital
Russian Federation
Russian Federation
Elena A. Sobko, MD, PhD, DSc (Med.), Professor of the Department of Hospital Therapy and Immunology with a Postgraduate Course, Krasnoyarsk State Medical University, Head of the Allergology Department, Krasnoyarsk Regional Clinical Hospital
1 Partizana Zheleznyaka Str., Krasnoyarsk, 660022,
3A Partizana Zheleznyaka Str., Krasnoyarsk, 660022
R. V. Khomchenkov
Krasnoyarsk State Medical University
Russian Federation
Russian Federation
Roman V. Khomchenkov, Head of the Department of Сardiac dispensary
1 Partizana Zheleznyaka Str., Krasnoyarsk, 660022
References
1. Martynenko T.I., Paraeva O.S., Chernoryuk G.E., Dronov S.V. [Verbal descriptors of dyspneah of pulmonary and cardiac genesis]. Sovremennyye problemy nauki i obrazovaniya 2019; 6:127 (in Russian). https://doi.org/10.17513/spno.29318
2. Paraeva O.S., Martynenko T.I., Chernogoryuk G.E., Dronov S.V. [Prognostic model of the diagnosis in patients with shortness of breath presumably pulmonary or cardiac origin]. Vestnik sovremennoy klinicheskoy meditsiny = The bulletin of contemporary clinical medicine 2019; 12(6):48–53 (in Russian). https://doi.org/10.20969/VSKM.2019.12(6).48-53
3. Parshall M.B., Schwartzstein R.M., Adams L., Banzett R.B., Manning H.L., Bourbeau J., Calverley P.M., Gift A.G., Harver A., Lareau S.C., Mahler D.A., Meek P.M., O'Donnell D.E. American thoracic society committee on dyspnea. An official American thoracic society statement: update on the mechanisms, assessment, and management of dyspnea. Am. J. Respir. Crit. Care Med. 2012; 185(4):435–452. https://doi.org/10.1164/rccm.201111-2042ST
4. Martynenko Т.I., Paraeva O.S., Dronov S.V., Shoykhet Ya.N. [Improvement in early differentiation of breathlessness due to pulmonary or cardiac disease]. Pul'monologiya = Russian Pulmonology 2014; 1:27–31 (in Russian). https://doi.org/10.18093/0869-0189-2014-0-1-27-31
5. Polyakov D.S., Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Artemjeva E.G., Badin Yu.V., Bakulina E.V., Vinogradova N.G., Galyavich A.S., Ionova T.S., Kamalov G.M., Kechedzhieva S.G., Koziolova N.A., Malenkova V.Yu., Malchikova S.V., Mareev Yu.V., Smirnova E.A., Tarlovskaya E.I., Shcherbinina E.V., Yakushin S.S. [Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study]. Kardiologiya = Kardiologiia 2021; 61(4):4–14 (in Russian). https://doi.org/10.18087/cardio.2021.4.n1628
6. Dushina A.G., Lopina E.A., Libis R.A. [Features of chronic heart failure depending on the left ventricular ejection fraction]. Rossiyskiy kardiologicheskiy zhurnal = Russian journal of cardiology 2019; 24(2):7–11 (in Russian). https://doi.org/10.15829/1560-4071-2019-2-7-11
7. Eyubova U.A. [Comparative efficacy of medication and cardiac resynchronization therapy in patients with heart failure with reduced ejection fraction]. Rossiyskiy kardiologicheskiy zhurnal = Russian journal of cardiology 2021; 26(8):83–88 (in Russian). https://doi.org/10.15829/1560-4071-2021-4491
8. Billebeau G., Vodovar N., Sadoune M., Launay J.M., Beauvais F., Cohen-Solal A. Effects of a cardiac rehabilitation programme on plasma cardiac biomarkers in patients with chronic heart failure. Eur. J. Prev. Cardiol. 2017; 24(11):1127– 1135. https://doi.org/10.1177/2047487317705488
9. Schwinger R.H.G. Pathophysiology of heart failure. Cardiovasc. Diagn. Ther. 2021; 11(1):263–276. https://doi.org/10.21037/cdt-20-302
10. Klimova A.A., Ambat'yello L.G., Smolyakova YE.V., Zykov K.A., Chazova I.E. [The frequency of detection of comorbid broncho-obstructive pathology in patients with arterial hypertension admitted to a specialized cardiological hospital]. Sistemnyye gipertenzii = Systemic Hypertension 2023; 20(1):35–43 (in Russian). https://doi.org/:10.26442/00403660.2019.01.000025
11. Stafeev A.N., Logvinenko N.I., Melnik A.V., Astrakov S.V. [Bronchial asthma and comorbid diseases. Variants of NO synthetases genetic polymorphisms]. Sovremennyye problemy nauki i obrazovaniya 2020; 4:138 (in Russian). https://doi.org/10.17513/spno.30062
12. Ostroumova O.D., Goloborodova I.V., Voyevodina N.Yu., Fomina V.M., Seregin A.A. [Asthma and cardiovascular disease]. Consilium Medicum 2018; 20(5):8–16 (in Russian). https://doi.org/10.26442/2075-1753_2018.5.8-16
13. Zhmurov D.V., Parfenteva M.A., Semenova Yu.V. [Bronchial asthma]. Colloquium-Journal 2020; 14-1(66):29-35 (in Russian). https://doi.org/10.24411/2520-6990-2020-11894
14. Ryabova A.Yu., Shapovalova T.G., Shashina M.M., Lekareva L.I., Kudishina M.M. [Prediction of heart remodeling in patients with bronchial asthma]. Saratovskij nauchno-medicinskij zhurnal = Saratov Journal of Medical Scientific Research 2018; 14 (1):49–52 (in Russian).
15. Reznik А.V. [Prediction and diagnosis of right ventricular heart failure and ventricular dysfunction during the exacerbation of bronchial asthma in children]. Klіnіchna pedіatrіya = Clinical Pediatrics 2018; 13(3):280–287 (in Ukraine). https://doi.org/10.22141/2224-0551.13.3.2018.132910
16. Agzamova K.R. [Bronchial asthma. Etiology and pathogenesis]. In: [All-Russian student Lomonosov readings: collection of articles of the All-Russian scientific and practical conference]. Petrozavodsk: Mezhdunarodnyy tsentr nauchnogo partnerstva «Novaya Nauka»; 2022:349–355 (in Russian).
17. Chuchalin A.G., Avdeyev S.N., Aysanov Z.R., Belevskiy A.S., Vasil'yeva O.S., Geppe N.A., Ignatova G.L., Knyazheskaya N.P., Malakhov A.B., Meshcheryakova N.N., Nenasheva N.M., Fassakhov R.S., Khaitov R.M., Il'ina N.I., Kurbacheva O.M., Astaf'yeva N.G., Demko I.V., Fomina D.S., Namazova-Baranova L.S., Baranov A.A., Vishneva Ye.A., Novik G.A. [Federal guidelines on diagnosis and treatment of bronchial asthma]. Pul'monologiya = Russian Pulmonology 2022; 32(3):393–447 (in Russian). https://doi.org/10.18093/0869-0189-2022-32-3-393-447
18. Ignatova G.L., Antonov V.N. [Possibilities of laboratory research methods in the differential diagnosis of respiratory tract diseases]. RMZH. Meditsinskoye obozreniye = Russian medical inquiry 2019; 3(9-1):14–17 (in Russian).
19. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. (Update 2018). Available at: https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-V1.3-002.pdf
20. Gasparyan A.Zh., Shlevkov N.B., Skvortsov A.A. [Possibilities of modern biomarkers for assessing the risk of developing ventricular tachyarrhythmias and sudden cardiac death in patients with chronic heart failure]. Kardiologiya = Kardiologiia 2020; 60(4):101–108 (in Russian). https://doi.org/10.18087/cardio.2020.4.n487
21. Larina V.N., Lunev V.I. [The value of biomarkers in the diagnosis and prognosis of heart failure in older age]. Ark hiv" vnutrenney meditsiny = The Russian Archives of Internal Medicine 2021; 11(2-58):98–110 (in Russian). https://doi.org/10.20514/2226-6704-2021-11-2-98-110
22. Kamardinov D.K., Songurov R.N., Ioshina V.I., Buziashvili Yu.I. [Soluble ST2 – as a biomarker, a tool for risk stratification and therapeutic target in patients with chronic heart failure]. Kardiologiya = Kardiologiia 2020; 60(2-58):111– 121 (in Russian). https://doi.org/10.18087/cardio.2020.2.n816
23. Alieva A.M., Reznik E.V., Pinchuk T.V., Arakelyan R.A., Valiev R.K., Rakhaev A.M., Tikhomirova A.S., Nikitin I.G. [Growth differentiation factor-15 (GDF-15) is a biological marker in heart failure]. Arkhiv" vnutrenney meditsiny = The Russian Archives of Internal Medicine 2023; 13(1-69):14–23. https://doi.org/10.20514/2226-6704-2023-13-1-14-23
24. Shepel R.N., Drapkina O.M. [Levels of angiogenesis markers in patients with different heart failure phenotypes]. Kardiovaskuljarnaja terapija i profilaktika = Cardiovascular Therapy and Prevention (Russian) 2022; 21(3): 36–41 (in Russian). https://doi.org/10.15829/1728-8800-2022-3230
25. Mahfouz R.A., El-dawei K., El-Dosoky I., Hamzah M. The impact of the eNOS Glu298→Asp polymorphisms on endothelial and diastolic function in non-diabetic offspring of diabetic parents. J. Med. Diagn. Meth. 2015; S2:S2003. https://doi.org/10.4172/2168-9784-S2003
26. Grakova E.V., Kopyeva K.V., Teplyakov A.T., Isakov L.K., Sinkova M.N., Tarasov N.I. [Role of fibrosis markers in assessing the risk of adverse cardiovascular events in patients with heart failure]. Rossiyskiy kardiologicheskiy zhurnal = Russian journal of cardiology. 2022; 27(7):76–82 (in Russian). https://doi.org/10.15829/1560-4071-2022-4753
27. Chaulin A.M., Grigor'yeva Yu.V [Galectin-3 as a prognostic biomarker of heart failure (a literature review)]. Mezhdunarodnyy nauchno-issledovatel'skiy zhurnal 2021; 2-3(104):55–56 (in Russian). https://doi.org/10.23670/IRJ.2021.103.2.072
28. Alieva AM, Pinchuk TV, Almazova II, Ettinger OA, Valiev RK, Batov MA, Nikitin IG. [Dinical value of blood biomarker st2 in patients with chronic heart failure]. Consilium Medicum. 2021; 23(6):522–526 (in Russian). https://doi.org/10.26442/20751753.2021.6.200606
29. Nymo S.H., Aukrust P., Kjekshus J., McMurray J.J., Cleland J.G., Wikstrand J., Muntendam P., Wienhues-Thelen U., Latini R., Askevold E.T., Gravning J., Dahl C.P., Broch K., Yndestad A., Gullestad L., Ueland T. Limited added value of circulating inflammatory biomarkers in chronic heart failure. JACC Heart. Fail. 2017; 5(4):256–264. https://doi.org/10.1016/j.jchf.2017.01.008
30. Grakova Ye.V., Kop'yeva K.V., Teplyakov A.T., OgurkovA O.N., Garganeyeva A.A., Garmayeva O.V. [Prognostic role of ST2 in patients with chronic heart failure of ischemic etiology and carbohydrate metabolism disorders]. Terapevticheskiy arkhiv 2019; 91 (1):32–37 (in Russian). https://doi.org/10.26442/00403660.2019.01.00002543
31. Wojtczak-Soska K., Pietrucha T., Sakowicz A., Lelonek M. Soluble ST2 protein in chronic heart failure is independent of traditional factors. Arch. Med. Sci. 2013; 9(1): 21–26. https://doi.org/10.5114/aoms.2013.33344
32. Rathjen F.G., Hodge R. Early days of tenascin-R research: Two approaches discovered and shed light on tenascinR. Front. Immunol. 2020; 8(11):612482. https://doi.org/10.3389/fimmu.2020.612482
33. Alieva A.M., Sozykin A.V., Teplova N.V., Reznik E.V., Izimarieva D.V., Novikova N.A., Lozovsky I.V., Averin Е.E., Valiev R.K., Nikitin I.G. [Tenascin-C as a cardiovascular marker]. Rossiyskiy kardiologicheskiy zhurnal= Russian journal of cardiology 2022; 27(8): 126–134 (in Russian). https://doi.org/10.15829/1560-4071-2022-5150
34. Santer D., Nagel F., Gonçalves I.F., Kaun C., Wojta J., Fagyas M., Krššák M., Balogh Á., Papp Z., Tóth A., Bánhegyi V., Trescher K., Kiss A., Podesser B.K. Tenascin-C aggravates ventricular dilatation and angiotensin-converting enzyme activity after myocardial infarction in mice. ESC Heart. Fail. 2020; 7(5):2113–2122. https://doi.org/10.1002/ehf2.12794
35. Imanaka-Yoshida K. Tenascin-C in heart diseases-the role of inflammation. Int. J. Mol. Sci. 2021; 22(11):5828. https://doi.org/10.3390/ijms22115828
36. Giblin S.P., Midwood K.S. Tenascin-C: form versus function. Cell Adh. Migr. 2015; 9(1-2):48–82. https://doi.org/10.4161/19336918.2014.987587
37. Avan A., Tavakoly Sany S.B., Ghayour-Mobarhan M., Rahimi H.R., Tajfard M., Ferns G. Serum C-reactive protein in the prediction of cardiovascular diseases: overview of the latest clinical studies and public health practice. J. Cell Physiol. 2018; 233(11):8508–8525. https://doi.org/10.1002/jcp.26791
38. Gellen B., Thorin-Trescases N., Thorin E., Gand E., Sosner P., Brishoual S., Rigalleau V., Montaigne D., Javaugue V., Pucheu Y., Gatault P., Piguel X., Hadjadj S., Saulnier P.J. Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort. Diabetologia 2020; 63(5):915–923. https://doi.org/10.1007/s00125-020-05108-5
39. Kanagala P., Arnold J.R., Khan J.N., Singh A., Gulsin G.S., Chan D.C.S., Cheng A.S.H., Yang J., Li Z., Gupta P., Squire I.B., McCann G.P., Ng L.L. Plasma Tenascin-C: a prognostic biomarker in heart failure with preserved ejection fraction. Biomarkers 2020; 25(7):556–565. https://doi.org/10.1080/1354750X.2020.1810319
40. Imanaka-Yoshida K., Tawara I., Yoshida T. Tenascin-C in cardiac disease: a sophisticated controller of inflammation, repair, and fibrosis. Am. J. Physiol. Cell. Physiol. 2020; 319(5):781–796. https://doi.org/10.1152/ajpcell.00353.2020
41. Ankudinov A.S., Kalyagin A.N. [Use of Galectin-3 in the Assessment of the Severity of Chronic Heart Failure As sociated with Rheumatoid Arthritis. Results of the Analysis]. Doktor.Ru 2021; 20(11):12–16 (in Russian). https://doi.org/10.31550/1727-2378-2021-20-11-12-16
42. Shchukin Yu.V., Berezin I.I., Medvedeva YE.A., Seleznev YE.I., D'yachkov V.A., Slatova L.N. [Galectin-3 as a marker and mediator of endogenous inflammation and nitrosylation oxidative stress in patients with chronic heart failure]. Rossiyskiy kardiologicheskiy zhurnal= Russian journal of cardiology 2013; 18(2):45–49 (in Russian). https://doi.org/10.15829/1560-4071-2013-2-45-49
43. Aliyeva A.M., Baykova I.E., Kislyakov V.A., Gasanova E.T., Almazova I.I., Pinchuk T.V., Fedulayev Yu.N., Zhbanov I.V., Perevertov V.A., Kovtyukh I.V., Nikitin I.G., Reznik Ye.V. [Galactin-3: diagnostic and prognostic value in patients with chronic heart failure]. Terapevticheskiy arkhiv 2019; 91(9):145–149 (in Russian). https://doi.org/10.26442/00403660.2019.09.000226
44. Kunutsor S.K., Laukkanen J.A., Bluemke D.A., Butler J., Khan H. Baseline and long-term gamma-glutamyltransferase, heart failure and cardiac arrhythmias in middle-aged Finnish men: Prospective study and pooled analysis of published evidence. Eur. J. Prev. Cardiol. 2016; 23(13):1354–1362. https://doi.org/10.1177/2047487316644086
45. Alieva A.M., Baykova I.E., Voronkova K.V., Teplova N.V., Shnakhova L.M., Valiev R.K., Elmurzaeva D.A., Rakhaev A.M., Kalova M.R., Nikitin I.G. [Gamma-glutamyl transpeptidase is a promising biological marker of heart failure]. Klinitsist = The Clinician 2022; 16(1):12–20 (in Russian). https://doi.org/10.17650/1818-8338-2022-16-1-K643
46. Alieva A.M., Teplova N.V., Batov M.A., Voronkova K.V., Valiev R.K., Shnakhova L.M., Pinchuk T.V., Rakhaev A.M., Kalova M.R., Nikitin I.G. [Pentraxin-3 – a promising biological marker in heart failure: literature review]. Consilium Medicum 2022; 24(1):53–59 (in Russian). https://doi.org/10.26442/20751753.2022.1.201382
Review
For citations:
Savich M.B., Demko I.V., Sobko E.A., Khomchenkov R.V. Potential markers for the diagnosis of heart failure in patients with asthma. Bulletin Physiology and Pathology of Respiration. 2024;(92):143-152. (In Russ.) https://doi.org/10.36604/1998-5029-2024-92-143-152
Views:
259
Email this article 